choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Reboxetine

Reboxetine Newsletter
  • New Data on Antidepressants and Stroke Risk 12 Aug 2019 11:10 GMT

    … Canada, told Medscape Medical News. The study was … ." Evaluating antidepressants beyond drug class may make … mianserin, mirtazapine, nefazodone, reboxetine, agomelatine, and viloxazine were … of a particular antidepressant treatment should be based …

  • AXSM Has Had An Awesome Run. What Awaits These 13 Biotech Stocks In Q2, 2019? 16 Apr 2019 08:34 GMT

    … phase II trial of AXS-12 (reboxetine) in narcolepsy … developing novel drugs for the treatment of neuropsychiatric … stage biotechnology company focused on targeted drugs to … Verrica Pharmaceuticals Inc. (VRCA) Verrica Pharmaceuticals is a medical dermatology …

  • Here's Why You Need To Keep An Eye On These Biotech Stocks 11 Mar 2019 10:55 GMT

    … Friday (Mar.8), AMAG Pharmaceuticals Inc. (AMAG) slipped nearly … is a biotechnology company developing next-generation medicines to … A phase II trial of AXS-12 (reboxetine) in narcolepsy … Cloth, approved for the treatment of primary axillary hyperhidrosis, …

  • Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy 30 Jan 2019 12:00 GMT

    Drug Administration (FDA) for the treatment of narcolepsy. Topline results from the CONCERT trialreboxetine) is a novel, oral, investigational medicine in development for the treatment … our ongoing clinical trials and anticipated clinical trials for our …

  • Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update 08 Aug 2019 11:00 GMT

    trials: the placebo-controlled GEMINI Phase 3 trialDrug Administration (FDA) Breakthrough Therapy designation for the treatment … inhibitor (reboxetine) being developed for the treatment of … next two months: BTIG Biotechnology Conference – August 12 …

  • Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy 17 Oct 2018 11:00 GMT

    FDA Office of Orphan Drug Products to promising drugsreboxetine) is a novel, oral, investigational medicine in development for the treatment … a Phase 3 trial in treatment resistant depression (TRD … ongoing clinical trials and anticipated clinical trials for …

  • Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy 16 Oct 2018 11:00 GMT

    … of Medicine. “Unfortunately, currently approved treatments are … open-label pilot trial, reboxetine treatment improved excessive daytime … investigational drug product not approved by the FDA. … ongoing clinical trials and anticipated clinical trials for …

  • The Pharmaceutical Industry in Contemporary Capitalism 28 Mar 2018 15:31 GMT

    … Food and Drug Administration (FDA), the European Medicines Agency ( … , Cerezyme, a treatment for Gaucher disease, … doctors and patients. Pharmaceutical corporations fund almost all pre-market clinical trials … of the antidepressant reboxetine versus placebo …

  • Antidepressant Effectiveness for Depressive Disorder Examined in New Study 23 Feb 2018 18:00 GMT

    … different drug treatment options.  In a report published this week in the medical … the pills is the best course. However, this new study indicates antidepressants … ; reboxetine, sold as edronax; and trazodone, sold as Desyrel. A drug was …

  • Antidepressants do work, concludes new study 22 Feb 2018 23:44 GMT

    … different drugs, with some antidepressants … duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine … antidepressants should always be the first line of treatment.” “Medicationtrials were funded by pharmaceutical companies, with overall 46 (9%) trials

Satisfied with the content?

Continue to create your account.